PDS Biotechnology (PDSB) Operating Income (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Operating Income came in at -$6.7 million in Q4 2025, up 9.32% YoY from -$6.1 million in Q4 2024, and up 18.0% on a QoQ basis from -$8.1 million in Q3 2025.
PDS Biotechnology (PDSB) Operating Income (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Operating Income data on file, last reported at -$6.7 million in Q4 2025.
- Quarterly Operating Income rose 9.32% year-over-year to -$6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$31.5 million (up 13.15% YoY) and the FY2025 annual result came in at -$31.5 million, up 13.15% from the prior year.
- Operating Income climbed to -$6.7 million in Q4 2025, from -$8.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$3.0 million in Q1 2021 to a low of -$18.8 million in Q4 2022.
- A 5-year average of -$8.7 million and a median of -$8.3 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income slumped 197.73% — and 2023, when it jumped 44.71%.
- Tracing PDSB's Operating Income over 5 years: stood at -$6.3 million in 2021, then slumped by 197.73% to -$18.8 million in 2022, then jumped by 44.71% to -$10.4 million in 2023, then climbed by 29.27% to -$7.4 million in 2024, then climbed by 9.32% to -$6.7 million in 2025.
- The last three Operating Income figures came in at -$6.7 million (Q4 2025), -$8.1 million (Q3 2025), and -$7.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | PDS Biotechnology | 11.97 Mn | 11.97 Mn | - | -6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.50 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Sep 30, 2025 | -8.14 Mn |
| Jun 30, 2025 | -7.62 Mn |
| Mar 31, 2025 | -9.11 Mn |
| Dec 31, 2024 | -7.36 Mn |
| Sep 30, 2024 | -10.18 Mn |
| Jun 30, 2024 | -8.68 Mn |
| Mar 31, 2024 | -10.10 Mn |
| Dec 31, 2023 | -10.41 Mn |
| Sep 30, 2023 | -10.52 Mn |
| Jun 30, 2023 | -12.70 Mn |
| Mar 31, 2023 | -9.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -7.28 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -8.48 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -5.11 Mn |